Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role

References

• Oliveira MS, Machado AS, Mendes ET, et al. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically ill patients receiving sustained low-efficiency dialysis. Clin Ther. 2020;42(4):625–633. doi:10.1016/j.clinthera.2020.02.01132199609
   PubMed Web of Science ®Google Scholar
• Qin X, Tsoi MF, Zhao X, Zhang L, Qi Z, Cheung BMY. Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016. BMC Nephrol. 2020;21(1):41. doi:10.1186/s12882-020-1704-432013870
   PubMed Web of Science ®Google Scholar
• Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. Pharmacotherapy. 2014;34(2):203–209. doi:10.1002/phar.132323798336
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp08043419106348
   PubMedGoogle Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa03632191793
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise T, et al. Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. J Pediatric Infect Dis Soc. 2020;9(3):281–284. doi:10.1093/jpids/piaa05732659787
   PubMed Web of Science ®Google Scholar
• Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother. 2010;54(8):3271–3279. doi:10.1128/AAC.01044-0920547818
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–39. doi:10.1086/49171216323118
   PubMed Web of Science ®Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004;2(4):289–300. doi:10.1038/nrmicro86215031728
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138–2144. doi:10.1001/archinte.166.19.213817060545
   PubMedGoogle Scholar
• Stove V, Coene L, Carlier M, De Waele JJ, Fiers T, Verstraete AG. Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance. Ther Drug Monit. 2015;37(2):180–187. doi:10.1097/FTD.000000000000012225072945
   PubMed Web of Science ®Google Scholar
• Ackerman BH, Taylor EH, Olsen KM, Abdel-Malak W, Pappas AA. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988;22(4):300–303. doi:10.1177/1060028088022004043371190
   PubMedGoogle Scholar
• Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP Ann Pharmacother. 1991;25(7–8):713–715. doi:10.1177/106002809102500701
   PubMedGoogle Scholar
• Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277–4282. doi:10.1128/AAC.01674-1021670191
   PubMed Web of Science ®Google Scholar
• Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother. 1993;37(5):1132–1136. doi:10.1128/AAC.37.5.11328517702
   PubMed Web of Science ®Google Scholar
• Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods. 1992;28(1):57–60. doi:10.1016/1056-8719(92)90066-A1392060
   PubMed Web of Science ®Google Scholar
• Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother. 1995;39(8):1842–1847. doi:10.1128/AAC.39.8.18427486929
   PubMed Web of Science ®Google Scholar
• Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int J Antimicrob Agents. 2009;34(6):555–560. doi:10.1016/j.ijantimicag.2009.08.00519782538
   PubMed Web of Science ®Google Scholar
• Oyaert M, Spriet I, Allegaert K, et al. Factors impacting unbound vancomycin concentrations in different patient populations. Antimicrob Agents Chemother. 2015;59(11):7073–7079. doi:10.1128/AAC.01185-1526349820
   PubMed Web of Science ®Google Scholar
• De Cock PA, Desmet S, De Jaeger A, et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? J Antimicrob Chemother. 2017;72(3):801–804. doi:10.1093/jac/dkw49527999035
   PubMed Web of Science ®Google Scholar
• Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clinl Microbiol Infect Dis. 2018;37(8):1503–1510. doi:10.1007/s10096-018-3277-8
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110. doi:10.2165/11539220-000000000-0000021142293
   PubMed Web of Science ®Google Scholar
• Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67(6):1305–1310. doi:10.1093/jac/dks06622382471
   PubMed Web of Science ®Google Scholar
• Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns. 1992;18(5):355–361. doi:10.1016/0305-4179(92)90032-P1445623
   PubMed Web of Science ®Google Scholar
• Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54(3):318–323. doi:10.1002/jcph.17524000044
   PubMed Web of Science ®Google Scholar
• Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8. doi:10.1007/s40262-012-0018-523150213
   PubMed Web of Science ®Google Scholar
• Kratzer A, Liebchen U, Schleibinger M, Kees MG, Kees F. Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions. J Chromatogr. 2014;961:97–102. doi:10.1016/j.jchromb.2014.05.021
   Web of Science ®Google Scholar
• Wang Y, Sheng G, Shi L, Cheng X. Increased serum total bilirubin-albumin ratio was associated with bilirubin encephalopathy in neonates. Biosci Rep. 2020;40(1).
   Web of Science ®Google Scholar
• Wu J, Wei R, Wang H, Li T, Ren W. Underlying the mechanism of vancomycin and human serum albumin interaction: a biophysical study. J Biochem Mol Toxicol. 2013;27(10):463–470. doi:10.1002/jbt.2151123922228
   PubMed Web of Science ®Google Scholar
• Cantu TG, Dick JD, Elliott DE, Humphrey RL, Kornhauser DM. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother. 1990;34(7):1459–1461. doi:10.1128/AAC.34.7.14592386376
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Wauters J, Vercammen I, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother. 2014;58(11):6782–6789. doi:10.1128/AAC.03641-1425182655
   PubMed Web of Science ®Google Scholar
• Tan CC, Lee HS, Ti TY, Lee EJ. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit. 1990;12(1):29–34. doi:10.1097/00007691-199001000-000062305418
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–1074. doi:10.1517/17425255.4.8.106518680441
   PubMed Web of Science ®Google Scholar
• Quale JM, O’Halloran JJ, DeVincenzo N, Barth RH. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother. 1992;36(7):1424–1426. doi:10.1128/AAC.36.7.14241510437
   PubMed Web of Science ®Google Scholar
• Nyman HA, Agarwal A, Senekjian HO, Leypoldt JK, Cheung AK. Removal of vancomycin administered during dialysis by a high-flux dialyzer. Hemodialysis Int. 2018;22(3):383–387. doi:10.1111/hdi.12637
   Web of Science ®Google Scholar